Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma

Journal of Thoracic Oncology 2017 October [Epub ahead of print] [Link] Patil NS, Righi L, Koeppen H, Zou W, Izzo S, Grosso F, Libener R, Loiacono M, Monica V, Buttigliero C, Novello S, Hegde PS, Papotti M, Kowanetz M, Scagliotti GV Abstract INTRODUCTION: Malignant pleural mesothelioma (MPM) is a rare, highly aggressive, relatively chemo- and…

Read More

Weight of evidence analysis for assessing the genotoxic potential of carbon nanotubes

Critical Reviews in Toxicology 2017 September [Epub ahead of print] [Link] Møller P, Jacobsen NR Abstract Carbon nanotube (CNT) is a nanomaterial that has received interest because of its high-tensile strength and low weight. Although CNTs differ substantially in physico-chemical properties, they share high aspect ratio which resembles that of asbestos and other fibers causing…

Read More

Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma

JAMA Oncology 2017 September [Epub ahead of print] [Link] Hung YP, Dong F, Watkins JC, Nardi V, Bueno R, Dal Cin P, Godleski JJ, Crum CP, Chirieac LR Abstract IMPORTANCE: Malignant peritoneal mesothelioma is a rare, aggressive tumor arising from the peritoneal lining, induced by asbestos, therapeutic radiation, or germline mutations. Nevertheless, the molecular features…

Read More

Magnetic nanoparticles-based therapy for malignant mesothelioma

Romanian Journal of Morphology and Embryology [2017] [Link] Mîndrilă I, Buteică SA, Mihaiescu DE, Burada F, Mîndrilă B, Predoi MC, Pirici I, Fudulu A, Croitoru O Abstract This work was aimed to analyze the versatility of the chick embryo chorioallantoic membrane (CAM) as in vivo model for the study of the malignant pleural mesothelioma (MPM)…

Read More

Targeting the epigenome in malignant pleural mesothelioma

Translational Lung Cancer Research 2017 June [Link] McLoughlin KC, Kaufman AS, Schrump DS Abstract Malignant pleural mesotheliomas (MPM) are notoriously refractory to conventional treatment modalities. Recent insights regarding epigenetic alterations in MPM provide the preclinical rationale for the evaluation of novel combinatorial regimens targeting the epigenome in these neoplasms.

Read More

Tumor suppressor candidate 2 (TUSC2, FUS-1) and human cancers

Discovery Medicine 2017 May [Link Rimkus T, Sirkisoon S, Harrison A, Lo HW Abstract Tumor suppressor candidate 2 (TUSC2, also known as FUS1) was identified in 2000 as a candidate tumor suppressor gene located in a region on chromosome 3p21.3 that is homozygously deleted in some lung and breast cancers. The deletion is rare in…

Read More

Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma

Expert Opinion of Investigational Drugs 2017 July 6 [Epub ahead of print] [Link] Guazzelli A, Bakker E, Tian K, Demonacos C, Krstic-Demonacos M, Mutti L Abstract INTRODUCTION: Malignant mesothelioma is a rare and lethal malignancy primarily affecting the pleura and peritoneum. Mesothelioma incidence is expected to increase worldwide and current treatments remain ineffective, leading to…

Read More